NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
22 December 2024
| Name: | PRESCIENT THERAPEUTICS LIMITED (PTX) | |||||||||
| ISIN: | AU000000PTX3 | |||||||||
| Date of Listing: | 19 December 1986 | |||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 006 569 106ABN: 56 006 569 106
Registration Date: 22 May 1986
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| PRESCIENT THERAPEUTICS LIMITED | 15/12/2014 | |
| VIRAX HOLDINGS LIMITED | 24/03/1997 | 15/12/2014 |
| RANCOO LIMITED | 24/03/1997 |
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Prescient Therapeutics Limited will be lifted from the commencement of trading on Tuesday, 26 May 2020, following the release by PTX of an announcement regarding a material licence agreement. | 26/05/2020 |
PTX obtains global, exclusive licence from University of Pennsylvania for an innovative universal immune receptor platform for the development of innovative cell therapies. PTX also has a global, non-exclusive licence from Oxford University to use the novel molecular binding system that is complementary with the Penn technology. PTX plans to incorporate the technologies from Penn, Oxford University and other assets, to build a universal chimeric immune receptor platform termed OmniCAR for next generation cell therapy product development. OmniCAR will enable in-house development of next generation engineered cell therapies and create opportunities for collaboration and business development in the cell therapy field for PTX. PTX's long term goal is to harness OmniCAR's innate adaptability and control to develop novel cell therapy products for new indications, and improve the cost, time and of effectiveness of delivering cell therapy products. | 26/05/2020 |
The securities of Prescient Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PTX, pending the release of an announcement regarding a material licence agreement. | 25/05/2020 |
name changed from Virax Holdings Limited | 15/12/2014 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 02/12/2014 |
The suspension of trading in the securities of Prescient Therapeutics Limited will be lifted from the commencement of trading on Tuesday, 26 May 2020, following the release by PTX of an announcement regarding a material licence agreement. | 26/05/2020 |
PTX obtains global, exclusive licence from University of Pennsylvania for an innovative universal immune receptor platform for the development of innovative cell therapies. PTX also has a global, non-exclusive licence from Oxford University to use the novel molecular binding system that is complementary with the Penn technology. PTX plans to incorporate the technologies from Penn, Oxford University and other assets, to build a universal chimeric immune receptor platform termed OmniCAR for next generation cell therapy product development. OmniCAR will enable in-house development of next generation engineered cell therapies and create opportunities for collaboration and business development in the cell therapy field for PTX. PTX's long term goal is to harness OmniCAR's innate adaptability and control to develop novel cell therapy products for new indications, and improve the cost, time and of effectiveness of delivering cell therapy products. | 26/05/2020 |
The securities of Prescient Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PTX, pending the release of an announcement regarding a material licence agreement. | 25/05/2020 |
name changed from Virax Holdings Limited | 15/12/2014 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 02/12/2014 |
Your browser may reflect a date of printing in American format.
I have a Transaction Confirmation Statement indicating my shares have been consolidated on a 1 to 10 basis, with a closing balance of 8400. Can I sell this so any loss made can be registered in my name for tax purposes? | 16/09/2019 17:10:46 |
consolidation of shares leaves me with only 156 shares of PTX nnDo you purchase small parcels for a fee so I can use the loss for tax purposes? | 11/04/2017 16:04:17 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 30/09/2024 | Gavin Shepherd | 235,908 | $0.040 | $9,435 |
| 26/03/2019 | James Campbell | 178,125 | $0.056 | $9,968 |
| 08/11/2016 | Paul Hopper | 50,000 | $0.100 | $5,000 |
| 26/07/2016 | Paul Hopper | 40,000 | $0.110 | $4,400 |
| 07/12/2015 | Paul Hopper | 50,000 | $0.093 | $4,650 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Steven Engle | Non Exec Chairman | 28/11/2014 |
| Steven Yatomi-Clarke | Managing Director, CEO | 28/11/2014 |
| Ellen Feigal | Independent Director | 15/05/2023 |
| Gavin Shepherd | Independent Director | 04/07/2024 |
| James Campbell | Non Exec Director | 28/11/2014 |
| Allen Ebens | Non Exec Director | 01/06/2020 |
| Melanie Leydin | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Paul Hopper | Non Exec Director | 02/06/2014 | 02/01/2020 |
| Rob Crombie | Managing Director | 18/06/2014 | 15/10/2015 |
| Wayne Millen | Executive Chairman | 02/09/2013 | 28/11/2014 |
| Roland Toder | Non Exec Director | 02/09/2013 | 28/11/2014 |
| Brendan de Kauwe | Non Exec Director | 02/09/2013 | 28/11/2014 |
| Michael Humphris | Chairman, Non Exec Director | 16/01/2008 | 02/09/2013 |
| Ian Pyman | Non Exec Director | 16/01/2008 | 02/09/2013 |
| John Morrison | Director | 13/03/2012 | 02/09/2013 |
| Larry Ward | CEO | 20/12/2007 | 24/08/2012 |
| Albert King | Non Exec Director | 16/01/2008 | 12/02/2011 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
